Oncogensis - Weir Flashcards

For each card in which the Gene Mutation is given, give the associated cancer diagnosis and treatment drug, otherwise just do what the card says.

1
Q

Define: Oncogenes

A

Genes in which mutations give rise to a gain of function or an enhanced level of function, leading to a malignancy. Mutated oncogenes are protooncogenes and usually encode growth or division promoting proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Define: Tumor Suppressor Genes

A

Usually encode negative regulators of growth and proliferation that protect cells from malignancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Li-Fraumeni Syndrome

A

Mutation in p53 (a TSG); no “brake” on the system (no other info given)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Cowden Syndrom

A

Mutation in PTEN (a TSG); removes a “brake” (no other info given)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

GIST (Gastrointestinal Stromal Tumor)

A

Due to mutation in c-Kit (an oncogene) (no other info given)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Mutation in EGFR kinase

A

Important in many cancers but specifically for lung cancers; Erlontinib (Tarceva)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Mutation in EML4-ALK

A

Lung Cancer; Crizotinib (Xalkori)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Mutation in EGFR receptor signaling

A

Head and Neck Cancer (Tonsil Cancer example); Cetuximab (Erbitux)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Goal is to inhibit VEGF in what cancer? What is treatment?

A

Glioblastoma; Bevacizumab (Avastin)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Mutation in a VHL (not exclusive, just example given)

A

Renal Cell Carcinoma; Treat with Sunitinib (Sutent) to inhibit VEGF kinases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

9:22 translocation

A

Chronic Myeloid Lukemia; treat with inhibition of bcr-abl tyrosine kinase (no drug name given)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How do you treat Estrogen Receptor positive breast cancer?

A

Tamoxifen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What inhibits mTOR when inhibiting estrogen receptors no longer works?

A

Everolimus (Afinitor)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How do you treat (HER-2) Estrogen Receptor negative breast cancer?

A

Trastuzumab (Herceptin); then Pertuzumab when HER-2 inhibitor no longer works

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How do you treat Prostate Cancer?

A

With the androgen receptor Enzalutamide (Zytiga)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

BRAF Mutation (B600)

A

Melanoma; Treat with Vemurafenib (Zelboraf)

17
Q

Mutation in Hedgehog system (PTCH Mutation)

A

Basal Cell Carcinomas; Treat with Vismodegib (Erivedge), a SMO inhibitor

18
Q

Many malignancies are caused by?

A

Mutation in oncogenes or TSGs

19
Q

Two inherited disorders predisposing to malignancies caused by mutations in TSHs are?

A

Li Fraumeni Syndrome and Cowden’s Syndrome

20
Q

One cancer accelerated by a c-Kit mutation is?

A

GIST (Gastrointestinal Stromal Tumor)

21
Q

Mutations in EGFR and ALK can lead to malignancies in a small percentage of what cancer?

A

Lung Cancer

22
Q

Usually multiple mutations are needed to overcome the body’s boundaries for what?

A

Cell Growth

23
Q

What can identify the mutation sites for many cancers and treat the problem specifically with targeted therapy?

A

Genomic Medicine

24
Q

Effective medicines have been made against specific targets in what cancers? 6 examples given

A

Breast, Lung, Head and Neck, Chronic Leukemias, Skin Cancers, and Brain Tumors

25
What are very important targets in Breast and Prostate cancers?
Hormone Receptors
26
Why are targeted treatments rarely curative?
When one pathway is targeted, mutations may develop to allow the cancer to progress around the therapy. Also, other pathways may increase to bypass the effect.